



ASX Announcement 10 September 2020

Elixinol Global Limited Appoints New Chair

- **Ms Helen Wiseman appointed Chair of Elixinol Global, brings strong governance and leadership skillset**
- **Mr Paul Benhaim to move to Non-Executive Director role as previously foreshadowed**
- **Recruitment process underway to recruit an additional Non-Executive Director to bring additional commercial experience to the Board**
- **Changes follow an important few months through which Elixinol Global has been aggressively repositioned toward high margin branded products, e-commerce and a lower cost operating environment**

Elixinol Global Limited (**Elixinol Global** or the **Company**) (**ASX:EXL; OTC:ELLXF**) is pleased to announce that Ms Helen Wiseman has been appointed Chair of the Elixinol Global Board, effective immediately, and that Mr Paul Benhaim will move into a Non-Executive Director role.

Ms Wiseman joined the Elixinol Global Board as Non-Executive Director in April 2020. She is an audit committee specialist with extensive international experience in food, pharmaceuticals, natural healthcare, professional services and manufacturing industries. She has chaired the group and regional audit committees of major JSE-listed Bid Corporation (JSE: BID) since 2016 and of the Bidvest (JSE: BVT) international foodservice business from 2011 - 2016. As a former partner of KPMG and previously named as one of the 2014 Australian Financial Review and Westpac 100 Women of Influence, Ms Wiseman brings diversity and seasoned governance skills to the role of Chair.

At Elixinol Global's Annual General Meeting on 30 July 2020, Mr Benhaim noted his intention to transition away from the role of Chairman once a suitable replacement was found.

Since joining the Board, Ms Wiseman has shown strong leadership capability in the areas of corporate governance and board strategy. Given her familiarity with Elixinol Global's operations and performance to date, Ms Wiseman has been selected as Chair to lead Elixinol Global through its next phase of growth. Since joining the Elixinol Global board in April 2020, Ms Wiseman has Chaired the Company's Audit & Risk Committee and the Remuneration & Nomination Committee. Ms Wiseman will continue to Chair the Audit & Risk Committee and Mr Benhaim will step into the role of Chair of the Remuneration & Nomination Committee, effective immediately.

As founder of the Company, with deep experience in the industry, Mr Benhaim will continue to bring invaluable insights to Elixinol Global and the Board. He commented: *"I am delighted that Helen has agreed to be appointed Chair of the Elixinol Global Board. Helen's in-depth*



experience will continue to be a great asset as we navigate complex and dynamic global regulatory environments.”

New Chair, Helen Wiseman commented, “I am very pleased to be transitioning into the role of Chair following what has been an important few months for Elixinol Global. Since joining in April, I’ve worked with the team to aggressively reposition the company, resetting our strategy to focus on e-commerce and higher margin, branded products while reducing costs and preparing to take advantage of the wellness interest that is emerging through the current macro-environment. We move forward with a very positive platform for generating further improved performance.”

Group CEO Mr Oliver Horn said: “Since joining, Helen has had an incredibly positive impact on our global business. Her board and large firm partner experience has been invaluable. She has brought a new level of compliance thinking to EXL global which is essential as we position ourselves to a trusted global nutraceuticals consumer business. On a personal level and being passionate about diversity, I am very proud to see a woman leading our board.”

Elixinol Global continues to focus on Board renewal and plans to add another independent director to its Board with extensive commercial industry experience in the US or Europe and ideally a track record within the e-commerce sector.

This document was authorised to be given to the ASX by the Board of the Company.

For more information please contact:

Ron Dufficy
Chief Financial Officer
ron.dufficy@elixinolglobal.com

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTC:ELLXF) is a global leader in the hemp derived CBD industry, innovating and selling hemp derived CBD products. The Company’s simplified business model is focusing on:

- In the Americas, innovating and selling high quality Elixinol branded hemp derived CBD products based in Colorado, USA
- In Europe & UK, educating and selling high quality Elixinol branded and co-branded hemp derived CBD products based in Amsterdam, The Netherlands
- In Australia, providing stronger unified planning and support across the group to enable the various regional offices to focus on operational strategy and execution through its Global Executive Office based in Sydney, Australia
- Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products
- Across the Rest of World, expanding distribution of Elixinol branded hemp derived CBD products through reputable distributors as key markets open.

See more at www.elixinolglobal.com